BCYC News and Press, Bicycle Therapeutics plc From 04/13/22

B. Riley analyst Kalpit Patel downgraded Bicycle Therapeutics (BCYC -4.3%) to Neutral from Buy with a price target of $33, down from $62, after speaking to a physician-scientist focused on treating patients with genitourinary malignancies. The doctor was unsure of BT8009's regulatory path and...

Bicycle Therapeutics (BCYC -11.2%) has its price objective reduced by equities research analysts at Needham & Co. from $85 to $75 in a research note issued. The firm presently has a “Buy” rating on the stock. Needham & Co.’s target price would suggest a poten...

Bicycle Therapeutics plc (NASDAQ: BCYC) is down 30% after the biotech firm pioneering novel and differentiated therapeutics class based on its bicyclin peptide tech announced preliminary first phase results from the Phase 1/2 study of BT8009. BT8009 is a second-generation BTC target...

The following slide deck was published by Bicycle Therapeutics plc in conjunction with this event. For further details see: Bicycle Therapeutics presents at AACR Annual Meeting 2022 - Slideshow

Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...

Bicycle Therapeutics Limited plc (NASDAQ: BCYC) reported interim Phase I results from the Phase I/II trial of BT8009, a second generation BTC that targets Nectin-4.  Results were presented on Sunday April 10th, at the 2022 American Association for Cancer Research Annual M...

The market yanked the rug out from under Bicycle Therapeutics (NASDAQ: BCYC) this morning in response to disappointing clinical trial results. Investors concerned about the company's experimental cancer treatments pushed the stock 29% lower as of 10:36 a.m. ET on Monday. Bicycle...

After announcing on Friday what it deemed promising results for bladder cancer candidate BT8009, leading to a rise in stock price, shares of Bicycle Therapeutics (NASDAQ:BCYC) are down 33% in premarket trading. Shares closed up ~24% on Friday. On that day, the company rele...

- 50% confirmed overall response rate, including one (13%) confirmed complete response in eight urothelial cancer patients dosed at 5.0mg/m 2 weekly - Median duration of response not yet reached in the 2.5mg/m 2 and 5.0mg/m 2 weekly cohorts; four of five responders in th...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...